OncoHost Recognized with BIG Innovation Award for Transformative Healthcare Solutions in 2026

OncoHost's Remarkable Achievement at the 2026 BIG Innovation Awards

On January 15, 2026, OncoHost, a pioneering technology firm, was awarded the prestigious 2026 BIG Innovation Award in the Health category. This recognition, presented by the Business Intelligence Group, highlights not only the overall excellence of OncoHost but also marks its significance in the landscape of precision medicine. Additionally, the company was celebrated as one of the Top 10 Innovators in the Small Business sector, underscoring its commitment to impactful technology.

Transforming Health Outcomes with Technology

OncoHost has been at the forefront of revolutionizing how precision medicine is approached, particularly for patients battling cancer. The company’s flagship platform, the PROphet®, employs cutting-edge technology and advances in plasma proteomics to enhance patient care significantly. It enables oncologists to predict patient responses to treatment, as well as potential adverse reactions, utilizing a mere blood sample before therapy begins.

In a landscape where traditional diagnostic methodologies may only provide limited insight, the PROphet® platform analyzes more than 7,000 circulating proteins in a patient’s bloodstream. This granular analysis allows for the creation of individualized predictive scores—equipping healthcare providers with the necessary tools to make informed treatment choices from the outset. The PROphetNSCLC® test specifically aids in deciding first-line immunotherapy options for patients with metastatic non-small cell lung cancer (NSCLC).

Reflecting on the significance of their win, Ofer Sharon, MD, CEO of OncoHost, stated, “We are honored to receive the 2026 BIG Innovation Award and to be designated a Top 10 Innovator among small businesses. This recognition validates our team's relentless focus on clinical impact—building a platform rooted in systemic biology that helps guide therapy decisions before treatment begins.”

Continuous Growth and Clinical Validation

Over the past year, OncoHost has put considerable effort into enhancing the biological explanatory strength and clinical relevance of the PROphet® platform. Notable advancements include a study published in the Journal for Immunotherapy of Cancer (JITC), which decoded resistance mechanisms in NSCLC—further advocating for precision oncology's efficacy and making a case for wider adoption.

The journey of OncoHost is backed by extensive research, including a large-scale prospective clinical trial that has successfully enrolled over 1,700 patients at more than 40 sites globally. This robust validation is crucial, allowing OncoHost to navigate the complex arena of precision diagnostics and biomarker development with confidence and scientific integrity.

Looking Towards the Future

The ongoing momentum of OncoHost’s initiatives positions the company as a leader in the emergent field of precision medicine. Its collaboration efforts are now expanding worldwide, bringing the PROphet® platform into discussions with oncology professionals globally who are ready to harness the power of data-driven insights to optimize treatment pathways.

In the words of Russ Fordyce, Chief Recognition Officer at the Business Intelligence Group, “The 2026 BIG Innovation Awards winners show that true innovation is no longer about chasing the latest buzzwords... These organizations are not just keeping pace with change—they are shaping the future of global business.”

As OncoHost continues to bridge the gap between laboratory intelligence and clinical application, many expect to see continued advancements that push the boundaries of what’s possible in healthcare.

For more details on the BIG Innovation Awards and the complete list of winners, you can visit Business Intelligence Group.

About OncoHost

Founded in Binyamina, Israel, and with a significant presence in Cary, North Carolina, OncoHost is dedicated to reshaping the precision medicine landscape. Its innovative PROphet® technology is a vital tool for oncologists, offering clear clinical utility and leading to improved survival outcomes for patients.

The company actively encourages ongoing collaboration and exploration within the medical community; to follow OncoHost's activities, their presence is notable across several platforms, including LinkedIn, X (formerly Twitter), Facebook, and YouTube.

For more information, visit OncoHost's website.